We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
AbbVie Inc.
Health Care · Pharmaceuticals
Post-Humira-LOE pharma re-up: Skyrizi + Rinvoq combined are tracking to surpass peak Humira revenue ($20B+ run-rate), with management guiding ex-Humira growth >$27B by 2027. 7B) added emraclidine for schizophrenia (Phase II miss late-2024 reset the bull case).
- Skyrizi + Rinvoq label expansion (IBD, PsA, AS) extending IO duopoly through 2030s
- Botox + Juvederm: pricing power + recurring procedure cadence, recession-resistant aesthetics
- Oncology re-tooling via ADC (Elahere) + Venclexta combos absorbing Imbruvica decline
- Dividend aristocrat heritage (Abbott split): >$6/share annual, 50+ year track record
- Humira US biosimilar erosion still rolling through 2026 ($15B+ revenue cliff absorbed but margin compression real)
- Cerevel emraclidine Phase II failure (2024) wiped $20B+ pipeline NPV; oncology pipeline less differentiated than $LLY $MRK
- IRA Medicare price negotiation hits Imbruvica 2026, Rinvoq + Skyrizi 2028 - political tail risk
- Net debt >$60B post-Cerevel + ImmunoGen; deleveraging competing with buybacks
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for ABBV - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.